Similarly, Tian et al. found that the small-molecule IAP inhibitor LCL16 targeted cIAP1, cIAP2, and XIAP, which are upregulated in HCC tumors, suggesting that LCL161 may be an effective agent in combination with paclitaxel for treating liver tumors 36. Here, XIAP is linked to hepatocellular carcinoma.